Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) CEO James Lanthier and Chief Scientific Officer Joseph Araujo talk to Proactive about the Toronto-based psychedelic medicines-focused group's latest update on the development of its first lead clinical candidate, MSP-1014. Lanthier and Araujo explain how MSP-1014 has demonstrated "superior efficacy and an improved safety profile" in head-to-head pre-clinical comparisons to generic psilocybin.
Mindset Pharma's lead therapy shows 'superior efficacy and improved safety' compared to psilocybin
